Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
Identifieur interne : 000E77 ( Main/Exploration ); précédent : 000E76; suivant : 000E78Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
Auteurs : Michael A. Davies [États-Unis] ; Philippe Saiag [France] ; Caroline Robert [France] ; Jean-Jacques Grob [France] ; Keith T. Flaherty [États-Unis] ; Ana Arance [Espagne] ; Vanna Chiarion-Sileni [Italie] ; Luc Thomas [France] ; Thierry Lesimple [France] ; Laurent Mortier [France] ; Stergios J. Moschos [États-Unis] ; David Hogg [Canada] ; Iván Márquez-Rodas [Espagne] ; Michele Del Vecchio [Italie] ; Céleste Lebbé [France] ; Nicolas Meyer [France] ; Ying Zhang [États-Unis] ; Yingjie Huang [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Georgina V. Long [Australie]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Céphalée (), Débit systolique (), Femelle, Fièvre (), Humains, Imagerie par résonance magnétique, Imidazoles (administration et posologie), Imidazoles (effets indésirables), Jeune adulte, Mutation, Mâle, Mélanome (génétique), Mélanome (imagerie diagnostique), Mélanome (secondaire), Mélanome (traitement médicamenteux), Oximes (administration et posologie), Oximes (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Protéines proto-oncogènes B-raf (génétique), Pyridones (administration et posologie), Pyridones (effets indésirables), Pyrimidinones (administration et posologie), Pyrimidinones (effets indésirables), Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du cerveau (génétique), Tumeurs du cerveau (imagerie diagnostique), Tumeurs du cerveau (secondaire), Tumeurs du cerveau (traitement médicamenteux), Études prospectives.
- MESH :
- administration et posologie : Imidazoles, Oximes, Pyridones, Pyrimidinones.
- effets indésirables : Imidazoles, Oximes, Protocoles de polychimiothérapie antinéoplasique, Pyridones, Pyrimidinones.
- génétique : Mélanome, Protéines proto-oncogènes B-raf, Tumeurs du cerveau.
- imagerie diagnostique : Mélanome, Tumeurs du cerveau.
- secondaire : Mélanome, Tumeurs du cerveau.
- traitement médicamenteux : Mélanome, Tumeurs du cerveau.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Céphalée, Débit systolique, Femelle, Fièvre, Humains, Imagerie par résonance magnétique, Jeune adulte, Mutation, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Études prospectives.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Brain Neoplasms (diagnostic imaging), Brain Neoplasms (drug therapy), Brain Neoplasms (genetics), Brain Neoplasms (secondary), Female, Fever (chemically induced), Headache (chemically induced), Humans, Imidazoles (administration & dosage), Imidazoles (adverse effects), Magnetic Resonance Imaging, Male, Melanoma (diagnostic imaging), Melanoma (drug therapy), Melanoma (genetics), Melanoma (secondary), Middle Aged, Mutation, Oximes (administration & dosage), Oximes (adverse effects), Prospective Studies, Proto-Oncogene Proteins B-raf (genetics), Pyridones (administration & dosage), Pyridones (adverse effects), Pyrimidinones (administration & dosage), Pyrimidinones (adverse effects), Stroke Volume (drug effects), Young Adult.
- MESH :
- chemical , administration & dosage : Imidazoles, Oximes, Pyridones, Pyrimidinones.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Imidazoles, Oximes, Pyridones, Pyrimidinones.
- chemically induced : Fever, Headache.
- diagnostic imaging : Brain Neoplasms, Melanoma.
- drug effects : Stroke Volume.
- drug therapy : Brain Neoplasms, Melanoma.
- genetics : Brain Neoplasms, Melanoma, Proto-Oncogene Proteins B-raf.
- secondary : Brain Neoplasms, Melanoma.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Aged, 80 and over, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Prospective Studies, Young Adult.
Abstract
Dabrafenib plus trametinib improves clinical outcomes in BRAF(V600)-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus trametinib has not been studied in active melanoma brain metastases. Here, we report results from the phase 2 COMBI-MB trial. Our aim was to build on the current body of evidence of targeted therapy in melanoma brain metastases through an evaluation of dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases.
DOI: 10.1016/S1470-2045(17)30429-1
PubMed: 28592387
Affiliations:
- Australie, Canada, Espagne, France, Italie, États-Unis
- Caroline du Nord, Catalogne, Communauté de Madrid, Hauts-de-France, Lombardie, Massachusetts, Midi-Pyrénées, New Jersey, Nord-Pas-de-Calais, Nouvelle-Galles du Sud, Occitanie (région administrative), Provence-Alpes-Côte d'Azur, Région Bretagne, Texas, Île-de-France
- Barcelone, Boulogne-Billancourt, Lille, Madrid, Marseille, Milan, Orsay, Paris, Rennes, Sydney, Toulouse
- Université Paris-Sud, Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000975
- to stream PubMed, to step Curation: 000972
- to stream PubMed, to step Checkpoint: 000972
- to stream Ncbi, to step Merge: 004934
- to stream Ncbi, to step Curation: 004934
- to stream Ncbi, to step Checkpoint: 004934
- to stream Main, to step Merge: 000E72
- to stream Main, to step Curation: 000E77
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.</title><author><name sortKey="Davies, Michael A" sort="Davies, Michael A" uniqKey="Davies M" first="Michael A" last="Davies">Michael A. Davies</name><affiliation wicri:level="2"><nlm:affiliation>Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mdavies@mdanderson.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Saiag, Philippe" sort="Saiag, Philippe" uniqKey="Saiag P" first="Philippe" last="Saiag">Philippe Saiag</name><affiliation wicri:level="3"><nlm:affiliation>Service de Dermatologie Générale et Oncologique, Hôpital A Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France; EA 4340, Université Versailles Saint-Quentin-en-Yvelines, Boulogne Billancourt, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Dermatologie Générale et Oncologique, Hôpital A Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France; EA 4340, Université Versailles Saint-Quentin-en-Yvelines, Boulogne Billancourt</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Boulogne-Billancourt</settlement></placeName></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation wicri:level="4"><nlm:affiliation>Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="3"><nlm:affiliation>Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille University, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille University, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><affiliation wicri:level="2"><nlm:affiliation>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Arance, Ana" sort="Arance, Ana" uniqKey="Arance A" first="Ana" last="Arance">Ana Arance</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Clinic of Barcelona, Carrer de Villarroel, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Clinic of Barcelona, Carrer de Villarroel, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma and Oesophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Padova, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Melanoma and Oesophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Padova</wicri:regionArea><wicri:noRegion>Padova</wicri:noRegion></affiliation></author><author><name sortKey="Thomas, Luc" sort="Thomas, Luc" uniqKey="Thomas L" first="Luc" last="Thomas">Luc Thomas</name><affiliation wicri:level="1"><nlm:affiliation>Service de Dermatologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Dermatologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite</wicri:regionArea><wicri:noRegion>Pierre-Bénite</wicri:noRegion><wicri:noRegion>Pierre-Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Lesimple, Thierry" sort="Lesimple, Thierry" uniqKey="Lesimple T" first="Thierry" last="Lesimple">Thierry Lesimple</name><affiliation wicri:level="3"><nlm:affiliation>Oncologie Dermatologique, Centre Eugène Marquis, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Oncologie Dermatologique, Centre Eugène Marquis, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Mortier, Laurent" sort="Mortier, Laurent" uniqKey="Mortier L" first="Laurent" last="Mortier">Laurent Mortier</name><affiliation wicri:level="3"><nlm:affiliation>Clinique de Dermatologie, Unité d'Onco-Dermatologie, Le Centre Hospitalier Régional Universitaire de Lille, University Lille 2, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinique de Dermatologie, Unité d'Onco-Dermatologie, Le Centre Hospitalier Régional Universitaire de Lille, University Lille 2, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Moschos, Stergios J" sort="Moschos, Stergios J" uniqKey="Moschos S" first="Stergios J" last="Moschos">Stergios J. Moschos</name><affiliation wicri:level="2"><nlm:affiliation>Melanoma Program, Medical Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Melanoma Program, Medical Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hogg, David" sort="Hogg, David" uniqKey="Hogg D" first="David" last="Hogg">David Hogg</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Cancer Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Clinical Cancer Research Unit, Princess Margaret Cancer Centre, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Marquez Rodas, Ivan" sort="Marquez Rodas, Ivan" uniqKey="Marquez Rodas I" first="Iván" last="Márquez-Rodas">Iván Márquez-Rodas</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Oncología Médica; Hospital General Universitario Gregorio Marañon, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Oncología Médica; Hospital General Universitario Gregorio Marañon, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Del Vecchio, Michele" sort="Del Vecchio, Michele" uniqKey="Del Vecchio M" first="Michele" last="Del Vecchio">Michele Del Vecchio</name><affiliation wicri:level="3"><nlm:affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Céleste" last="Lebbé">Céleste Lebbé</name><affiliation wicri:level="3"><nlm:affiliation>APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Hôpital Saint Louis Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Hôpital Saint Louis Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Meyer, Nicolas" sort="Meyer, Nicolas" uniqKey="Meyer N" first="Nicolas" last="Meyer">Nicolas Meyer</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Zhang, Ying" sort="Zhang, Ying" uniqKey="Zhang Y" first="Ying" last="Zhang">Ying Zhang</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Huang, Yingjie" sort="Huang, Yingjie" uniqKey="Huang Y" first="Yingjie" last="Huang">Yingjie Huang</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Mookerjee, Bijoyesh" sort="Mookerjee, Bijoyesh" uniqKey="Mookerjee B" first="Bijoyesh" last="Mookerjee">Bijoyesh Mookerjee</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="4"><nlm:affiliation>Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28592387</idno><idno type="pmid">28592387</idno><idno type="doi">10.1016/S1470-2045(17)30429-1</idno><idno type="wicri:Area/PubMed/Corpus">000975</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000975</idno><idno type="wicri:Area/PubMed/Curation">000972</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000972</idno><idno type="wicri:Area/PubMed/Checkpoint">000972</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000972</idno><idno type="wicri:Area/Ncbi/Merge">004934</idno><idno type="wicri:Area/Ncbi/Curation">004934</idno><idno type="wicri:Area/Ncbi/Checkpoint">004934</idno><idno type="wicri:Area/Main/Merge">000E72</idno><idno type="wicri:Area/Main/Curation">000E77</idno><idno type="wicri:Area/Main/Exploration">000E77</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.</title><author><name sortKey="Davies, Michael A" sort="Davies, Michael A" uniqKey="Davies M" first="Michael A" last="Davies">Michael A. Davies</name><affiliation wicri:level="2"><nlm:affiliation>Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mdavies@mdanderson.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Saiag, Philippe" sort="Saiag, Philippe" uniqKey="Saiag P" first="Philippe" last="Saiag">Philippe Saiag</name><affiliation wicri:level="3"><nlm:affiliation>Service de Dermatologie Générale et Oncologique, Hôpital A Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France; EA 4340, Université Versailles Saint-Quentin-en-Yvelines, Boulogne Billancourt, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Dermatologie Générale et Oncologique, Hôpital A Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France; EA 4340, Université Versailles Saint-Quentin-en-Yvelines, Boulogne Billancourt</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Boulogne-Billancourt</settlement></placeName></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation wicri:level="4"><nlm:affiliation>Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="3"><nlm:affiliation>Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille University, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille University, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><affiliation wicri:level="2"><nlm:affiliation>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Arance, Ana" sort="Arance, Ana" uniqKey="Arance A" first="Ana" last="Arance">Ana Arance</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Clinic of Barcelona, Carrer de Villarroel, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Clinic of Barcelona, Carrer de Villarroel, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma and Oesophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Padova, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Melanoma and Oesophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Padova</wicri:regionArea><wicri:noRegion>Padova</wicri:noRegion></affiliation></author><author><name sortKey="Thomas, Luc" sort="Thomas, Luc" uniqKey="Thomas L" first="Luc" last="Thomas">Luc Thomas</name><affiliation wicri:level="1"><nlm:affiliation>Service de Dermatologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Dermatologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite</wicri:regionArea><wicri:noRegion>Pierre-Bénite</wicri:noRegion><wicri:noRegion>Pierre-Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Lesimple, Thierry" sort="Lesimple, Thierry" uniqKey="Lesimple T" first="Thierry" last="Lesimple">Thierry Lesimple</name><affiliation wicri:level="3"><nlm:affiliation>Oncologie Dermatologique, Centre Eugène Marquis, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Oncologie Dermatologique, Centre Eugène Marquis, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Mortier, Laurent" sort="Mortier, Laurent" uniqKey="Mortier L" first="Laurent" last="Mortier">Laurent Mortier</name><affiliation wicri:level="3"><nlm:affiliation>Clinique de Dermatologie, Unité d'Onco-Dermatologie, Le Centre Hospitalier Régional Universitaire de Lille, University Lille 2, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinique de Dermatologie, Unité d'Onco-Dermatologie, Le Centre Hospitalier Régional Universitaire de Lille, University Lille 2, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Moschos, Stergios J" sort="Moschos, Stergios J" uniqKey="Moschos S" first="Stergios J" last="Moschos">Stergios J. Moschos</name><affiliation wicri:level="2"><nlm:affiliation>Melanoma Program, Medical Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Melanoma Program, Medical Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hogg, David" sort="Hogg, David" uniqKey="Hogg D" first="David" last="Hogg">David Hogg</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Cancer Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Clinical Cancer Research Unit, Princess Margaret Cancer Centre, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Marquez Rodas, Ivan" sort="Marquez Rodas, Ivan" uniqKey="Marquez Rodas I" first="Iván" last="Márquez-Rodas">Iván Márquez-Rodas</name><affiliation wicri:level="3"><nlm:affiliation>Servicio de Oncología Médica; Hospital General Universitario Gregorio Marañon, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio de Oncología Médica; Hospital General Universitario Gregorio Marañon, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Del Vecchio, Michele" sort="Del Vecchio, Michele" uniqKey="Del Vecchio M" first="Michele" last="Del Vecchio">Michele Del Vecchio</name><affiliation wicri:level="3"><nlm:affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Céleste" last="Lebbé">Céleste Lebbé</name><affiliation wicri:level="3"><nlm:affiliation>APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Hôpital Saint Louis Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Hôpital Saint Louis Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Meyer, Nicolas" sort="Meyer, Nicolas" uniqKey="Meyer N" first="Nicolas" last="Meyer">Nicolas Meyer</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Zhang, Ying" sort="Zhang, Ying" uniqKey="Zhang Y" first="Ying" last="Zhang">Ying Zhang</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Huang, Yingjie" sort="Huang, Yingjie" uniqKey="Huang Y" first="Yingjie" last="Huang">Yingjie Huang</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Mookerjee, Bijoyesh" sort="Mookerjee, Bijoyesh" uniqKey="Mookerjee B" first="Bijoyesh" last="Mookerjee">Bijoyesh Mookerjee</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="4"><nlm:affiliation>Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Brain Neoplasms (diagnostic imaging)</term><term>Brain Neoplasms (drug therapy)</term><term>Brain Neoplasms (genetics)</term><term>Brain Neoplasms (secondary)</term><term>Female</term><term>Fever (chemically induced)</term><term>Headache (chemically induced)</term><term>Humans</term><term>Imidazoles (administration & dosage)</term><term>Imidazoles (adverse effects)</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Melanoma (diagnostic imaging)</term><term>Melanoma (drug therapy)</term><term>Melanoma (genetics)</term><term>Melanoma (secondary)</term><term>Middle Aged</term><term>Mutation</term><term>Oximes (administration & dosage)</term><term>Oximes (adverse effects)</term><term>Prospective Studies</term><term>Proto-Oncogene Proteins B-raf (genetics)</term><term>Pyridones (administration & dosage)</term><term>Pyridones (adverse effects)</term><term>Pyrimidinones (administration & dosage)</term><term>Pyrimidinones (adverse effects)</term><term>Stroke Volume (drug effects)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Céphalée ()</term><term>Débit systolique ()</term><term>Femelle</term><term>Fièvre ()</term><term>Humains</term><term>Imagerie par résonance magnétique</term><term>Imidazoles (administration et posologie)</term><term>Imidazoles (effets indésirables)</term><term>Jeune adulte</term><term>Mutation</term><term>Mâle</term><term>Mélanome (génétique)</term><term>Mélanome (imagerie diagnostique)</term><term>Mélanome (secondaire)</term><term>Mélanome (traitement médicamenteux)</term><term>Oximes (administration et posologie)</term><term>Oximes (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Protéines proto-oncogènes B-raf (génétique)</term><term>Pyridones (administration et posologie)</term><term>Pyridones (effets indésirables)</term><term>Pyrimidinones (administration et posologie)</term><term>Pyrimidinones (effets indésirables)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs du cerveau (génétique)</term><term>Tumeurs du cerveau (imagerie diagnostique)</term><term>Tumeurs du cerveau (secondaire)</term><term>Tumeurs du cerveau (traitement médicamenteux)</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Imidazoles</term><term>Oximes</term><term>Pyridones</term><term>Pyrimidinones</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Imidazoles</term><term>Oximes</term><term>Pyridones</term><term>Pyrimidinones</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Imidazoles</term><term>Oximes</term><term>Pyridones</term><term>Pyrimidinones</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Fever</term><term>Headache</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Brain Neoplasms</term><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Stroke Volume</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Brain Neoplasms</term><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Imidazoles</term><term>Oximes</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Pyridones</term><term>Pyrimidinones</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Brain Neoplasms</term><term>Melanoma</term><term>Proto-Oncogene Proteins B-raf</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Mélanome</term><term>Protéines proto-oncogènes B-raf</term><term>Tumeurs du cerveau</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Mélanome</term><term>Tumeurs du cerveau</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Mélanome</term><term>Tumeurs du cerveau</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Brain Neoplasms</term><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term><term>Tumeurs du cerveau</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Mutation</term><term>Prospective Studies</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Céphalée</term><term>Débit systolique</term><term>Femelle</term><term>Fièvre</term><term>Humains</term><term>Imagerie par résonance magnétique</term><term>Jeune adulte</term><term>Mutation</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dabrafenib plus trametinib improves clinical outcomes in BRAF(V600)-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus trametinib has not been studied in active melanoma brain metastases. Here, we report results from the phase 2 COMBI-MB trial. Our aim was to build on the current body of evidence of targeted therapy in melanoma brain metastases through an evaluation of dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Italie</li><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Catalogne</li><li>Communauté de Madrid</li><li>Hauts-de-France</li><li>Lombardie</li><li>Massachusetts</li><li>Midi-Pyrénées</li><li>New Jersey</li><li>Nord-Pas-de-Calais</li><li>Nouvelle-Galles du Sud</li><li>Occitanie (région administrative)</li><li>Provence-Alpes-Côte d'Azur</li><li>Région Bretagne</li><li>Texas</li><li>Île-de-France</li></region><settlement><li>Barcelone</li><li>Boulogne-Billancourt</li><li>Lille</li><li>Madrid</li><li>Marseille</li><li>Milan</li><li>Orsay</li><li>Paris</li><li>Rennes</li><li>Sydney</li><li>Toulouse</li></settlement><orgName><li>Université Paris-Sud</li><li>Université de Sydney</li></orgName></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Davies, Michael A" sort="Davies, Michael A" uniqKey="Davies M" first="Michael A" last="Davies">Michael A. Davies</name></region><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><name sortKey="Huang, Yingjie" sort="Huang, Yingjie" uniqKey="Huang Y" first="Yingjie" last="Huang">Yingjie Huang</name><name sortKey="Mookerjee, Bijoyesh" sort="Mookerjee, Bijoyesh" uniqKey="Mookerjee B" first="Bijoyesh" last="Mookerjee">Bijoyesh Mookerjee</name><name sortKey="Moschos, Stergios J" sort="Moschos, Stergios J" uniqKey="Moschos S" first="Stergios J" last="Moschos">Stergios J. Moschos</name><name sortKey="Zhang, Ying" sort="Zhang, Ying" uniqKey="Zhang Y" first="Ying" last="Zhang">Ying Zhang</name></country><country name="France"><region name="Île-de-France"><name sortKey="Saiag, Philippe" sort="Saiag, Philippe" uniqKey="Saiag P" first="Philippe" last="Saiag">Philippe Saiag</name></region><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Céleste" last="Lebbé">Céleste Lebbé</name><name sortKey="Lesimple, Thierry" sort="Lesimple, Thierry" uniqKey="Lesimple T" first="Thierry" last="Lesimple">Thierry Lesimple</name><name sortKey="Meyer, Nicolas" sort="Meyer, Nicolas" uniqKey="Meyer N" first="Nicolas" last="Meyer">Nicolas Meyer</name><name sortKey="Mortier, Laurent" sort="Mortier, Laurent" uniqKey="Mortier L" first="Laurent" last="Mortier">Laurent Mortier</name><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><name sortKey="Thomas, Luc" sort="Thomas, Luc" uniqKey="Thomas L" first="Luc" last="Thomas">Luc Thomas</name></country><country name="Espagne"><region name="Catalogne"><name sortKey="Arance, Ana" sort="Arance, Ana" uniqKey="Arance A" first="Ana" last="Arance">Ana Arance</name></region><name sortKey="Marquez Rodas, Ivan" sort="Marquez Rodas, Ivan" uniqKey="Marquez Rodas I" first="Iván" last="Márquez-Rodas">Iván Márquez-Rodas</name></country><country name="Italie"><noRegion><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name></noRegion><name sortKey="Del Vecchio, Michele" sort="Del Vecchio, Michele" uniqKey="Del Vecchio M" first="Michele" last="Del Vecchio">Michele Del Vecchio</name></country><country name="Canada"><noRegion><name sortKey="Hogg, David" sort="Hogg, David" uniqKey="Hogg D" first="David" last="Hogg">David Hogg</name></noRegion></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E77 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E77 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28592387
|texte= Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28592387" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |